Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

NCT05226507 is registered in ClinicalTrials.gov with Nuvectis Pharma, Inc. as lead sponsor.

NCT NCT05226507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05226507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Lead sponsor
Nuvectis Pharma, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2021
Completion date
January 1, 2025
Enrollment
45 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, arid1a gene mutation, ovarian cancer, ovarian clear cell adenocarcinoma, ovarian clear cell carcinoma, ovarian clear cell tumor, ovarian endometrioid adenocarcinoma, ovarian endometrioid tumor